Key result
Elevated periprocedural hs-CRP in COPD patients undergoing PCI is linked to ~89% more in-hospital MACEs.
Why the study?
Does elevated hs-CRP at admission predict increased in-hospital MACEs in COPD patients undergoing PCI?
Cohort (n=378)
Does elevated hs-CRP at admission predict increased in-hospital MACEs in COPD patients undergoing PCI?
Absolute Event Rate: 15.5% vs 8.2%
p-value: p=0.041
Elevated periprocedural hs-CRP is an independent predictor of in-hospital MACE and longer hospital stay in COPD patients undergoing PCI.
No takes yet. Share an insight, caveat, or question.
Should not yet change periprocedural risk assessment in COPD patients undergoing PCI; supports prospective validation of hs-CRP-guided strategies.
Zhang et al. (2014) conducted a cohort in Chronic obstructive pulmonary disease (COPD) and coronary artery disease (n=378). Elevated hs-CRP (≥3 mg/L) vs. Lower hs-CRP (<3 mg/L) was evaluated on In-hospital composite major adverse cardiovascular events (MACEs) (p=0.041). Elevated periprocedural hs-CRP (≥3 mg/L) in COPD patients undergoing PCI was associated with a higher rate of in-hospital MACEs compared to lower hs-CRP levels (15.5% vs 8.2%, P=0.041).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: